Factors Affecting Survival on Biologic Treatments in Patients with Rheumatoid Arthritis: A Single-Center Study From Turkey

Authors : Beliz KARATAŞ, Barış YILMAZER

Pages : 73-84

Doi:10.17517/ksutfd.1068756

View : 10 | Download : 6

Publication Date : 2023-03-16

Article Type : Research Paper

Abstract :Objective: In our study, we aimed to determine the factors affecting survival on biologic treatment in adult rheumatoid arthritis insert ignore into journalissuearticles values(RA); patients using biolog- ical drugs. Materials and Methods: In our study, the data of 245 patients who were followed up with the diagnosis of RA in the Rheumatology Clinic of Trakya University Medical Faculty Hospital between 2013 and 2016 were analyzed retrospectively. 37 patients were excluded due to missing data. The data of the remaining 208 patients were evaluated. Results: In our study, we found that drug survival was reduced by 0.48 times insert ignore into journalissuearticles values(95% CI 0.23-0.97); in elderly patients and 3 times insert ignore into journalissuearticles values(95% CI 1.09-10.3); in females. According to the results of our study, drug survival is shortened 8 times insert ignore into journalissuearticles values(95% CI 2.12-32.5); in patients with hyperlipidemia and 1.03 times insert ignore into journalissuearticles values(95% CI 1.01-1.04); in patients with high pretreatment erythrocyte sedimentation rate insert ignore into journalissuearticles values(ESR);. In addition, we found that shorter drug survival 9.2 times insert ignore into journalissuearticles values(95% CI 2.4-35.3); in patients with Hepatitis B surface antigen insert ignore into journalissuearticles values(HBsAg); positivity, 2.9 times insert ignore into journalissuearticles values(95% CI 1.3-6.4); in patients with antibody positivity against citrullinated protein insert ignore into journalissuearticles values(ACPA);, in patients using glucocorticoids 0.36 times insert ignore into journalissuearticles values(95% CI 0.17-0.76);. Despite that; in patients with chronic kidney disease, drug survival was prolonged by 0.18 times insert ignore into journalissuearticles values(95% CI 0.06-0.57);. Conclusion: When starting biologic drugs in RA patients, some parameters may help to predict drug survival. According to the order of effect; while HBsAg positivity, presence of hyperlipidemia, female gender, ACPA positivity, high ESR, advanced age and glucocorticoid use were negative markers for drug survival; chronic kidney damage can be a positive marker.
Keywords : Biyolojik ajanlar, Romatoid artrit, Tümör nekroz faktör